Difference between revisions of "Team:EPFL"

Line 6: Line 6:
  
 
     <main>
 
     <main>
         <section class="spotlight bg-primary bg-cover bg-size--cover" data-spotlight="fullscreen" style="background-color #FF0033;">
+
         <section class="spotlight bg-primary bg-cover bg-size--cover" data-spotlight="fullscreen" style="background-color #f03;">
 
             <span class="mask bg-primary alpha-4"></span>
 
             <span class="mask bg-primary alpha-4"></span>
 
             <div class="spotlight-holder py-lg pt-lg-xl">
 
             <div class="spotlight-holder py-lg pt-lg-xl">

Revision as of 13:26, 23 August 2018

iGEM EPFL 2018 iGEM EPFL 2018

CAPOEIRA

Cancer Personalized Encapsulin Immunotherapy and Relapse Assay

What is CAPOEIRA ?

While cancer is still the disease of the 21st century, new insights and approaches are changing the landscape of cancer therapy. Cancer immunotherapy is becoming a key technique for the successful fight against cancer. The goal of cancer immunotherapy is to harness the immune system in the fight against cancer. The project that the EPFL 2018 iGEM team is presenting is focused on the development of a new therapeutic approach to target specific types of cancer using immunotherapy methods, with a focus on vaccines. Furthermore, the project aims to integrate the personalized medicine approaches, by using patient-specific neoantigens to trigger the immune system and produce the response against cancer. The project is exhaustive and can be divided into the following parts:

Detection

Detection of cancer patient specific tumor mutations and neoantigens

Vaccine

Expression of the neoantigens and the adjuvant using encapsulin

Immune response

Maturation of dendritic cells and T-cells

Follow up

Detection of cancer relapse using liquid biopsies of ctDNA and cancer miRNA